Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 11/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27132918 | 1.00 | NR1H2 (0.47) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL27704578 | 0.83 | NR1H2 (0.48) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL6617875 | 0.81 | NR1H2 (0.46) | NR1H2NR1H3GPR119RORCSTS | |
| SCHEMBL4976100 | 0.77 | NR1H2 (0.46) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL4068506 | 0.77 | NR1H2 (0.46) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL28815574 | 0.76 | NR1H2 (0.53) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL18642718 | 0.76 | NR1H2 (0.53) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL16004573 | 0.76 | NR1H2 (0.53) | NR1H2NR1H3GPR119RORCKDM1A | |
| SCHEMBL27738898 | 0.76 | NR1H2 (0.57) | NR1H2NR1H3GPR119RORC | |
| SCHEMBL27738889 | 0.76 | NR1H2 (0.57) | NR1H2NR1H3GPR119RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | NR1H2 1824/4885NR1H3 1990/4885GPR119 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.